Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of miRNA in preparation of chemotherapy drug resistance evaluation kit for high-grade serous epithelial ovarian cancer

A technology for drug resistance and ovarian cancer, applied in the field of biomedicine, can solve the problems of different histological features and stages, insufficient identification ability to guide clinical decision-making, and influence the identification ability of prediction models

Pending Publication Date: 2019-02-15
TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
View PDF5 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Third, the study claims that the predictive model has prognostic significance independent of histological features. Although the TCGA dataset is characterized by high-grade serous ovarian cancer, the histological features and stages of the samples in the OC179 and OC263 datasets are significantly different.
In summary, the stage of ovarian cancer patients may affect the discriminative ability of the prediction model
Fifth, although the prediction model can significantly distinguish the high-risk group from the low-risk group, the AUC of the ROC curve for judging the discrimination ability of the prediction model is only 0.58±0.02 in the TCGA data set
This level of discriminatory power is insufficient to guide clinical decision-making

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of miRNA in preparation of chemotherapy drug resistance evaluation kit for high-grade serous epithelial ovarian cancer
  • Application of miRNA in preparation of chemotherapy drug resistance evaluation kit for high-grade serous epithelial ovarian cancer
  • Application of miRNA in preparation of chemotherapy drug resistance evaluation kit for high-grade serous epithelial ovarian cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Example 1: Screening of miRNA markers related to platinum chemotherapy resistance in high-grade serous ovarian cancer

[0046] Application of miRNA in preparing reagents for evaluating chemotherapy resistance or recurrence of advanced serous epithelial ovarian cancer:

[0047] 1. Collection of patient tissue and clinical pathological data

[0048] Among 349 patients with high-grade serous epithelial ovarian cancer, 101 were used as the training set, 98 were used as the internal validation set, and 150 were used as the independent validation set.

[0049] All included specimens meet the following entry criteria:

[0050] (1) All patients were primary high-grade serous ovarian cancer and did not receive any anti-cancer treatment before surgery.

[0051] (2) After the staging of ovarian cancer, the pathological type of the specimen was reviewed by the pathologist as high-grade serous ovarian cancer.

[0052] (3) The specimens used for RNA extraction are four 10 μm paraffin specimens, ...

Embodiment 2

[0084] Example 2. Preparation of miRNA detection kit

[0085] Kit based on RT-qPCR technology

[0086] In this embodiment, the miRNA detection kit based on nucleic acid amplification includes the following components:

[0087] (1) Total RNA extraction reagent: environmentally friendly dewaxing agent, tissue lysis buffer, proteinase K, Trizol solution, chloroform, isopropanol, ethanol, DEPC water;

[0088] (2) miRNA reverse transcription reagents: reverse transcriptase, RNase inhibitor, reverse transcription buffer, dNTP mixture.

[0089] (3) miRNA reverse transcription primers: miR-1287, miR-3131, miR-335, miR-4419, miR-4468, miR-96 reverse transcription primers, and U6 reverse transcription primers used as internal controls.

[0090] (4) PCR detection reagents for miRNA: Taq enzyme, Mg2+, PCR buffer, dNTP mixture, nucleic acid dye.

[0091] (5) miRNA nucleic acid amplification primers: miR-1287, miR-3131, miR-335, miR-4419, miR-4468, miR-96 upstream primer, miRNA qPCR universal downstrea...

Embodiment 3

[0095] Example 3. Clinical application of miRNA detection based on RT-qPCR technology

[0096] The paraffin sections of 50 subjects were obtained, and the RT-qPCR method as in Example 2 was used to detect miR-1287, miR-3131, miR-335, miR-4419, miR-4468, and miR-96. Judge the subject’s platinum sensitivity based on the measured results, and the results are as follows:

[0097] Among the 50 subjects, 29 were platinum-sensitive patients and 21 were platinum-resistant patients. According to the cut-off value in Example 1, 22 of the 29 platinum-sensitive patients were detected as platinum-sensitive patients, and 16 of the 21 platinum-resistant patients were detected as platinum-resistant patients.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of miRNA in preparation of a diagnostic reagent for predicting platinum chemotherapy drug resistance of high-grade serous ovarian cancer. The miRNA comprises miR-1287, miR-3131, miR-335, miR-4419, miR-4468 and miR-96. The invention also provides application for analyzing and detecting platinum chemotherapy drug resistance of high-grade serous ovarian cancer onthe basis of the determination of the expression quantity of miR-1287, miR-3131, miR-335, miR-4419, miR-4468 and miR-96, and the application has better accuracy than the existing method for predictingplatinum chemotherapy drug resistance of high-grade serous ovarian cancer.

Description

Technical field [0001] The present invention belongs to the field of biomedicine; more specifically, it relates to the application of microRNA in the preparation of a kit for predicting platinum-based chemotherapy resistance of high-grade serous epithelial ovarian cancer, and is clinically sensitive to platinum-based chemotherapy of patients with ovarian cancer And progression-free survival provides auxiliary diagnosis. Background technique [0002] Epithelial ovarian cancer (hereinafter referred to as ovarian cancer) is one of the most common malignant tumors of the female reproductive system. Its fatality rate is the highest among all gynecological tumors. The 5-year survival rate has been hovering at 30-40% for a long time. Although the incidence of ovarian cancer in my country It ranks third in female tumors, but the fatality rate is in the first place. The standard treatment for epithelial ovarian cancer is surgery and platinum-paclitaxel-based combination chemotherapy. How...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886G16H70/40
CPCG16H70/40C12Q1/6886C12Q2600/178C12Q2600/158C12Q2600/106
Inventor 马丁陈刚孙朝阳郭恩松
Owner TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com